Skip to main content

Advertisement

Table 1 Aberrant somatic hypermutation of RHOH in human cancers.

From: The small GTPase RhoH is an atypical regulator of haematopoietic cells

Cancer Type and number of samples ASHM Frequency Remarks Mutation Frequency for RhoH Ref
Hodgkin lymphoma (HL) Nodular lymphocyte predominant HL (n = 10) Classic HL (n = 9) 80% 55.5%   11.1% 0% [51]
Mature B-cell neoplasms Diffuse large B-cell lymphoma (n = 39) >50%   46% [35]
Mature B-cell neoplasms Nodal marginal zone lymphoma and Splenic marginal zone lymphoma (n = 55) 13% Not c-MYC 3.6% [44]
Mature B-cell neoplasms Mucosa-associated lymphoid tissue lymphoma (n = 17) Extranodal diffuse large B-cell lymphoma (n = 17) 76.5% 100%   11.8% 47.1% [45]
Mature B-cell neoplasms Primary CNS lymphoma (n = 10) 90%   70% [46]
Mature B-cell neoplasms Primary cutaneous large B-cell lymphoma, leg type (n = 13) Primary cutaneous follicle centre lymphoma (n = 19) 54% 53% Not PIM1 30.7% 10.5% [47]
Mature B-cell neoplasms Follicular lymphoma Diffuse large B-cell lymphoma (n = 9) Chronic lymphocytic leukaemia Diffuse large B-cell lymphoma (n = 9) 33.3% 55.5% 11.1% 22.2%   33% 11.1% [48]
Mature B-cell neoplasms Chronic lymphocytic leukaemia (n = 15) Diffuse large B-cell lymphoma (n = 13) Prolymphocytic transformation (n = 8) 26.7% 100% 100% Not PIM1 0% 46.1% 25% [49]
Mature B-cell neoplasms Diffuse large B-cell lymphoma (n = 100) >50%   35% [50]
Mature B-cell neoplasms Mediastinal B-cell lymphoma (n = 6) 100% Not PIM1 66% [72]
Mature B-cell neoplasms Low grade follicular lymphoma (n = 32) Transformed follicular lymphoma (n = 26) 75% 77%   16% 31% [73]
Immunodeficiency-associated lympho-proliferative disorders Post-transplant LD (n = 21) Polymorphic PTLD (n = 8) Monomorphic PTLD (n = 12) 45% 12.5% 66.7%   20% 20% 40% [52]
Immunodeficiency-associated lympho-proliferative disorders AIDS-associated non-Hodgkin lymphoma (n = 39) 48.7%   23.1% [53]
Immunodeficiency-associated lympho-proliferative disorders HCV-associated non-Hodgkin lymphoma (n = 9) 31%   13% [54]
  1. Summary of currently available data on RHOH as a target for ASHM. The general ASHM frequency is defined by the frequency for mutations in at least one of the following genes: PIM1, PAX5, MYC and RHOH, except where otherwise indicated.